Jean Tang, MD, PhD is co-founder of PellePharm and serves on the PellePharm board of directors. She is a practicing dermatologist and associate professor of dermatology at Stanford University. Dr. Tang discusses PellePharm and it’s lead drug candidate, Patidegib.
Patidegil is entering a Phase 3 trial for patients suffering from Gorlin Syndrome, a rare, genetic, disease characterized by mutations in the tumor suppressor gene encoding Patched1 (PTCH1), which acts as the primary inhibitor of the hedgehog signaling pathway. This leads to hundreds of basal cell carcinomas, especially on the face and sun-exposed areas.
Patients suffering from Gorlin Syndrome and BCCs have a genetic mutation in the tumor suppressor gene encoding Patched1 (PTCH1), which acts as the primary inhibitor of the hedgehog signaling pathway.
Patidegib was developed to work by turning off the hedgehog signaling pathway. It is intended to chemically enhances a naturally occurring hedgehog pathway inhibitor by blocking the Smoothened signal, which allows cells to function normally and stop the overproduction of tumors found in patients with Gorlin Syndrome and BCCs.
Topical patidegib gel has shown early promise in a phase 2 clinical study for the mitigation of the BCC tumors in Gorlin Syndrome, with topline data announced in 2017. Topline data from a United States-based phase 2 clinical trial of topical patidegib for sporadic BCCs will be released in early 2018.